Zhengye Biotechnology (NASDAQ:ZYBT) Shares Down 2% – Should You Sell?

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) fell 2% during mid-day trading on Wednesday . The stock traded as low as $0.9572 and last traded at $1.00. 11,188 shares were traded during mid-day trading, a decline of 22% from the average session volume of 14,273 shares. The stock had previously closed at $1.02.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Zhengye Biotechnology in a research report on Friday, January 9th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Zhengye Biotechnology Stock Performance

The business has a 50-day simple moving average of $1.59 and a 200-day simple moving average of $4.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.49 and a quick ratio of 1.10.

Institutional Investors Weigh In On Zhengye Biotechnology

A number of hedge funds have recently added to or reduced their stakes in ZYBT. WINTON GROUP Ltd purchased a new stake in Zhengye Biotechnology during the 3rd quarter worth about $56,000. Jane Street Group LLC purchased a new stake in Zhengye Biotechnology during the 2nd quarter worth about $1,158,000. Invesco Ltd. acquired a new position in shares of Zhengye Biotechnology during the 2nd quarter worth about $220,000. Geode Capital Management LLC purchased a new position in Zhengye Biotechnology in the second quarter valued at approximately $174,000. Finally, Millennium Management LLC purchased a new position in shares of Zhengye Biotechnology in the 3rd quarter valued at $38,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.